CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy

Khalilullah Mia-Jan, So Young Jung, Ikyong Kim, Sung Soo Oh, Eun Hee Choi, Sei Jin Chang, Tae Young Kang, Meeyon Cho

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Cancer stem cells (CSCs) are notorious for their capacity of tumor progression, metastasis or resistance to chemo-radiotherapy. However, the undisputed role of cancer stem marker, CD133, in colorectal cancers (CRCs) is not clear yet.Methods: We assessed 271 surgically-resected stage II and III primary CRCs with (171) and without (100) adjuvant therapy after surgery. CD133 expression was analyzed by immunohistochemical (IHC) staining and real-time RT-PCR. CD133 promoter methylation was quantified by pyrosequencing.Results: The CD133 IHC expression was significantly correlated with mRNA expression (p=0.0257) and inversely correlated with the promoter methylation (p=0.0001). CD133 was expressed more frequently in rectal cancer (p=0.0035), and in moderately differentiated tumors (p=0.0378). In survival analysis, CD133 expression was not significantly correlated with overall survival (OS) (p=0.9689) as well as disease-free survival (DFS) (p=0.2103). However, CD133+ tumors were significantly associated with better OS in patients with adjuvant therapy compared to those without adjuvant therapy (p<0.0001, HR 0.125, 95% CI 0.052-0.299). But the patients with CD133- tumors did not show any significant difference of survival according to adjuvant therapy (p=0.055, HR 0.500, 95% CI 0.247-1.015).Conclusions: In stage II and III CRCs, CD133 IHC expression may signify the benefit for adjuvant therapy although it is not an independent prognostic factor.

Original languageEnglish
Article number166
JournalBMC Cancer
Volume13
DOIs
Publication statusPublished - 2013 Mar 28

Fingerprint

Colorectal Neoplasms
Neoplasms
Methylation
Survival
Therapeutics
Neoplastic Stem Cells
Rectal Neoplasms
Survival Analysis
Disease-Free Survival
Real-Time Polymerase Chain Reaction
Radiotherapy
Staining and Labeling
Neoplasm Metastasis
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

@article{00429fd46f6446ba8f6d67a1908e4d19,
title = "CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy",
abstract = "Background: Cancer stem cells (CSCs) are notorious for their capacity of tumor progression, metastasis or resistance to chemo-radiotherapy. However, the undisputed role of cancer stem marker, CD133, in colorectal cancers (CRCs) is not clear yet.Methods: We assessed 271 surgically-resected stage II and III primary CRCs with (171) and without (100) adjuvant therapy after surgery. CD133 expression was analyzed by immunohistochemical (IHC) staining and real-time RT-PCR. CD133 promoter methylation was quantified by pyrosequencing.Results: The CD133 IHC expression was significantly correlated with mRNA expression (p=0.0257) and inversely correlated with the promoter methylation (p=0.0001). CD133 was expressed more frequently in rectal cancer (p=0.0035), and in moderately differentiated tumors (p=0.0378). In survival analysis, CD133 expression was not significantly correlated with overall survival (OS) (p=0.9689) as well as disease-free survival (DFS) (p=0.2103). However, CD133+ tumors were significantly associated with better OS in patients with adjuvant therapy compared to those without adjuvant therapy (p<0.0001, HR 0.125, 95{\%} CI 0.052-0.299). But the patients with CD133- tumors did not show any significant difference of survival according to adjuvant therapy (p=0.055, HR 0.500, 95{\%} CI 0.247-1.015).Conclusions: In stage II and III CRCs, CD133 IHC expression may signify the benefit for adjuvant therapy although it is not an independent prognostic factor.",
author = "Khalilullah Mia-Jan and Jung, {So Young} and Ikyong Kim and Oh, {Sung Soo} and Choi, {Eun Hee} and Chang, {Sei Jin} and Kang, {Tae Young} and Meeyon Cho",
year = "2013",
month = "3",
day = "28",
doi = "10.1186/1471-2407-13-166",
language = "English",
volume = "13",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy. / Mia-Jan, Khalilullah; Jung, So Young; Kim, Ikyong; Oh, Sung Soo; Choi, Eun Hee; Chang, Sei Jin; Kang, Tae Young; Cho, Meeyon.

In: BMC Cancer, Vol. 13, 166, 28.03.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy

AU - Mia-Jan, Khalilullah

AU - Jung, So Young

AU - Kim, Ikyong

AU - Oh, Sung Soo

AU - Choi, Eun Hee

AU - Chang, Sei Jin

AU - Kang, Tae Young

AU - Cho, Meeyon

PY - 2013/3/28

Y1 - 2013/3/28

N2 - Background: Cancer stem cells (CSCs) are notorious for their capacity of tumor progression, metastasis or resistance to chemo-radiotherapy. However, the undisputed role of cancer stem marker, CD133, in colorectal cancers (CRCs) is not clear yet.Methods: We assessed 271 surgically-resected stage II and III primary CRCs with (171) and without (100) adjuvant therapy after surgery. CD133 expression was analyzed by immunohistochemical (IHC) staining and real-time RT-PCR. CD133 promoter methylation was quantified by pyrosequencing.Results: The CD133 IHC expression was significantly correlated with mRNA expression (p=0.0257) and inversely correlated with the promoter methylation (p=0.0001). CD133 was expressed more frequently in rectal cancer (p=0.0035), and in moderately differentiated tumors (p=0.0378). In survival analysis, CD133 expression was not significantly correlated with overall survival (OS) (p=0.9689) as well as disease-free survival (DFS) (p=0.2103). However, CD133+ tumors were significantly associated with better OS in patients with adjuvant therapy compared to those without adjuvant therapy (p<0.0001, HR 0.125, 95% CI 0.052-0.299). But the patients with CD133- tumors did not show any significant difference of survival according to adjuvant therapy (p=0.055, HR 0.500, 95% CI 0.247-1.015).Conclusions: In stage II and III CRCs, CD133 IHC expression may signify the benefit for adjuvant therapy although it is not an independent prognostic factor.

AB - Background: Cancer stem cells (CSCs) are notorious for their capacity of tumor progression, metastasis or resistance to chemo-radiotherapy. However, the undisputed role of cancer stem marker, CD133, in colorectal cancers (CRCs) is not clear yet.Methods: We assessed 271 surgically-resected stage II and III primary CRCs with (171) and without (100) adjuvant therapy after surgery. CD133 expression was analyzed by immunohistochemical (IHC) staining and real-time RT-PCR. CD133 promoter methylation was quantified by pyrosequencing.Results: The CD133 IHC expression was significantly correlated with mRNA expression (p=0.0257) and inversely correlated with the promoter methylation (p=0.0001). CD133 was expressed more frequently in rectal cancer (p=0.0035), and in moderately differentiated tumors (p=0.0378). In survival analysis, CD133 expression was not significantly correlated with overall survival (OS) (p=0.9689) as well as disease-free survival (DFS) (p=0.2103). However, CD133+ tumors were significantly associated with better OS in patients with adjuvant therapy compared to those without adjuvant therapy (p<0.0001, HR 0.125, 95% CI 0.052-0.299). But the patients with CD133- tumors did not show any significant difference of survival according to adjuvant therapy (p=0.055, HR 0.500, 95% CI 0.247-1.015).Conclusions: In stage II and III CRCs, CD133 IHC expression may signify the benefit for adjuvant therapy although it is not an independent prognostic factor.

UR - http://www.scopus.com/inward/record.url?scp=84875296927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875296927&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-13-166

DO - 10.1186/1471-2407-13-166

M3 - Article

VL - 13

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 166

ER -